EVO ICL › Is EVO ICL safe?

Medically reviewed by Gurpal Virdi, MD, refractive and cataract surgeon and ICL-sizing researcher · Last reviewed: 25 August 2026

Is EVO ICL safe?

Name: Is EVO ICL safe?
Creator: Gurpal Virdi, MD

Short answer. In the three-year FDA study of 629 eyes, anterior subcapsular cataract occurred in 0.16% of eyes, with no cases of pupillary block or pigment dispersion and a safety index of 1.25. Nearly half of eyes — 48.9% — saw better after surgery than they had with glasses beforehand.

The three-year FDA trial numbers

The prospective multicentre FDA study followed 629 eyes of 327 subjects across 14 US clinical sites, with 92.1% completing the three-year visit. Mean postoperative uncorrected distance visual acuity was −0.053 logMAR, which is 20/20 or better. 48.9% of eyes gained one or more lines of best-corrected acuity, meaning they saw better after surgery than they previously could with glasses or contacts. The safety index was 1.25 at three years, anterior subcapsular cataract occurred in 0.16% of eyes, and there were no cases of pupillary block or pigment dispersion (PubMed).

What the real-world reporting data shows

A retrospective review of 17,482 adverse-event reports submitted to the FDA between 2015 and 2023 found that over 70% recorded no clinical signs, symptoms or conditions at all (Chen Q, Ni S, Yan H, et al. Ophthalmol Ther. 2025;14(11):2753–2767, full text).

One caveat deserves stating plainly, because it is almost always left out when these figures are quoted: those are proportions of reports, not incidence rates. The dataset has no denominator of total implants, so it describes the shape of what gets reported rather than how often anything happens. Anyone presenting those percentages as your personal risk is misreading the paper.

The complication most within a surgeon's control

Sizing. Our review of exchanges and explants at a US high-volume centre found that lens size, not the implant or the surgical technique, drives most of the reoperations that do occur (Clinical Ophthalmology, 2025). A lens that vaults too high or too low is a sizing decision made before the operation ever starts.

This is why the useful question for a prospective surgeon is not how many ICLs they have done, but how they choose the size: what imaging they use, whether they rely on a single white-to-white formula, and what their own exchange rate is. See how sizing is actually done.

The specific risks, one at a time

"Safe" is not a single number, and the individual risks behave quite differently from one another.

Cataract formation. The historical concern with phakic lenses, because an implant sitting close to the natural lens can interfere with the flow of nutrients across its surface. The EVO design addresses this with a central port that allows aqueous to circulate, and the three-year FDA data reflects it: anterior subcapsular cataract in 0.16% of 629 eyes. Vault matters here, since a lens sitting too low sits closer to the natural lens than it should.

Raised intraocular pressure. Can occur early, usually from retained viscoelastic in the first day or two, and is typically transient and treatable. Longer-term pressure issues relate to angle anatomy and are the reason the angle is measured carefully beforehand. The three-year study reported no pupillary block, the specific mechanism that made older phakic lenses require a peripheral iridotomy.

Endothelial cell loss. The corneal endothelium does not regenerate, so any intraocular surgery costs some cells. This is why endothelial cell density is measured before surgery and why a low count is a genuine contraindication. It is the metric to ask about at long-term follow-up.

Night vision symptoms. Halos and glare around lights, most noticeable in the first months and typically settling as the brain adapts. Larger pupils in dim conditions make them more likely. They are common enough that they should be discussed as an expected part of the early course rather than as a complication.

Retinal detachment. Not caused by the ICL as such, but highly myopic eyes carry an elevated baseline risk regardless of whether they have surgery, and that risk persists afterwards. A dilated retinal examination beforehand, and knowing the warning signs afterwards, matters more in these eyes than in any other group.

What "safety index 1.25" actually means

Safety index is the ratio of best-corrected visual acuity after surgery to best-corrected acuity before it. A value of 1.0 means the eye sees exactly as well as it did with its best glasses beforehand. 1.25 means it sees better.

That is counterintuitive until you consider what a strong spectacle lens does. Minifying a high myope's image, introducing distortion, and sitting a centimetre in front of the eye all degrade the retinal image in ways a lens inside the eye does not. This is why 48.9% of eyes in the trial gained a line or more of best-corrected acuity, and it is the aspect of ICL that patients most consistently underestimate beforehand.

How to read safety statistics that get quoted at you

Two failure modes are worth recognising, because both appear constantly in material on this subject.

The first is the missing denominator. Adverse-event databases collect reports, not populations. A figure like "4.78% of cases had raised intraocular pressure" drawn from such a database means 4.78% of the reports, not of the surgeries performed. Since the vast majority of uneventful surgeries generate no report at all, treating those proportions as your personal risk overstates it by an unknown and probably large factor.

The second is the missing timeframe. "Cataract rate of 0.16%" means something quite different at three years than at fifteen. The FDA figure above is a three-year number and should be quoted as one. Longer-term data exists but is less complete, and anyone offering you a precise lifetime figure is extrapolating.

The part you can actually influence

Most of the risks above are properties of the procedure and your anatomy. Sizing is the one that is a decision, and it is made before the operation begins.

The lens comes in four sizes and the same eye vaults differently across them. Choose too large and the lens sits high, crowding the angle. Too small and it sits low, close to the natural lens. Traditional sizing uses white-to-white corneal diameter as a proxy for the internal dimension where the lens actually rests, which is a correlation rather than a measurement. Our own review of exchanges and explants found sizing to be the dominant driver of reoperation.

So the useful questions for a surgeon are not about volume. They are: do you image the anterior segment rather than relying on white-to-white alone, what method do you use to choose size, and what is your own exchange rate? A surgeon who tracks that last number is telling you something about how they practise. See how sizing is done.

What to ask a Bay Area ICL surgeon

The San Francisco Bay Area has a high concentration of refractive surgeons, from San Francisco itself through Palo Alto and the Peninsula down into San Jose and Silicon Valley, and volume claims are easy to find. The harder question, and the one the data above points to, is method. Ask how the surgeon sizes the lens: whether they image the anterior segment or rely on white-to-white corneal diameter alone, what sizing method or nomogram they use, and what their own exchange rate is. A surgeon anywhere in the Bay Area who tracks that last number is telling you something useful about how they practise.

Is EVO ICL safe?

The three-year FDA trial numbers

What the real-world reporting data shows

The complication most within a surgeon's control

The specific risks, one at a time

What "safety index 1.25" actually means

How to read safety statistics that get quoted at you

The part you can actually influence

What to ask a Bay Area ICL surgeon

Related questions